Danavorexton (TAK-925): an orexin receptor 2 agonist as a new 'arousal' agent.

Lambert, David G; Hirota, Kazuyoshi

Lambert, David G; Hirota, Kazuyoshi.

Afiliação

Lambert DG; Department of Cardiovascular Sciences, Anaesthesia, Critical Care and Pain Management, University of Leicester, Hodgkin Building, Leicester, UK. Electronic address: dgl3@le.ac.uk.
Hirota K; Department of Anesthesiology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Br J Anaesth ; 132(3): 466-468, 2024 Mar.

Article em En | MEDLINE | ID: mdl-38346840

ABSTRACT

ABSTRACT

A preclinical study in animals has further characterised a new 'arousal' agent. Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation. Although danavorexton reverses opioid sedation, it does not compromise analgesia. This could be a useful addition to the postoperative drug cupboard.

Assuntos

Analgésicos Opioides; Nível de Alerta; Piperidinas; Sulfonamidas; Animais; Receptores de Orexina; Orexinas; Analgésicos Opioides/farmacologia

Palavras-chave

arousal; danavorexton; opioid; orexin; orexin receptor-2; sedation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Nível de Alerta / Sulfonamidas / Analgésicos Opioides Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google